Why MiniMed Stock Was Soaring This Week

Investors have been highly optimistic about MiniMed Group (NASDAQ: MMED) throughout recent trading days. This enthusiasm was warranted, as the company reported its first-quarter fiscal 2027 results, which surpassed revenue forecasts. Consequently, MiniMed's shares surged nearly 19% in the past week, according to data from S&P Global Market Intelligence.

In 2009, a "Double Down" signal appeared, signaling a rare opportunity for a chipmaker named Nvidia. Similarly, a "Total Conviction" signal is currently shining brightly for MiniMed, despite its much smaller size compared to Nvidia, a leading tech company.

MiniMed's fiscal 2027 net sales reached $843 million, marking a robust 17% increase year-over-year. International sales accounted for $603 million, up 18% compared to the same period last year, while U.S. sales were $240 million, growing by 13% YoY. The company achieved breakeven, a significant improvement from a $19 million net loss in the same period of the previous fiscal year, which beat analyst estimates.

A notable highlight of the quarter was the launch of MiniMed Flex, an insulin pump integrated with the Simplera glucose monitoring device. MiniMed believes this product will expand its user base, boost competitive conversions, and foster significant new account growth. The firm also raised its full-year revenue guidance, projecting a 10.5% increase over the fiscal 2026 figure, up from an initial 10% expectation. Management affirmed its previous EBITDA growth guidance of 16%.

MiniMed's focus on diabetes care, a significant global patient population, provides a strong foundation for its future growth. Although the stock is a niche player, its recent momentum and product rollouts suggest notable promise, making it an attractive consideration for potential investors.